Logo

ADIL

Adial Pharmaceuticals, Inc.

ADIL

Adial Pharmaceuticals, Inc. • NASDAQ
$0.31 ▲ 1.16% (+0.00)
Market Cap $7.52 M
52w High $1.30
52w Low $0.22
Dividend Yield 0%
P/E -0.52
Volume 298.76K
Outstanding Shares 23.99M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $1.764M ▼ $-1.794M ▲ 0% $-0.08 ▲ $-1.794M ▲
Q2-2025 $0 $1.883M ▼ $-1.959M ▲ 0% $-0.18 ▲ $-1.883M ▲
Q1-2025 $0 $2.267M ▲ $-2.229M ▼ 0% $-0.34 ▼ $-2.267M ▼
Q4-2024 $0 $1.941M ▼ $-2.071M ▲ 0% $-0.11 ▲ $-2.071M ▲
Q3-2024 $0 $2.211M $-2.192M 0% $-0.38 $-2.211M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $4.606M ▼ $5.66M ▼ $1.155M ▼ $4.505M ▼
Q2-2025 $5.915M ▲ $6.802M ▲ $1.211M ▼ $5.591M ▲
Q1-2025 $2.366M ▼ $3.451M ▼ $1.324M ▲ $2.127M ▼
Q4-2024 $3.751M ▼ $5.044M ▼ $975.858K ▲ $4.068M ▼
Q3-2024 $5.204M $6.713M $829.046K $5.884M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-1.794M ▼ $-1.833M ▼ $0 $524.682K ▼ $-1.309M ▼ $-1.833M ▼
Q2-2025 $0 ▲ $-1.749M ▼ $0 ▼ $5.298M ▲ $3.549M ▲ $-1.749M ▼
Q1-2025 $-2.229M ▼ $-1.585M ▼ $150K ▲ $50.648K ▲ $-1.385M ▲ $-1.585M ▼
Q4-2024 $-2.071M ▲ $-1.454M ▲ $0 $0 ▼ $-1.454M ▼ $-1.454M ▲
Q3-2024 $-2.192M $-1.694M $0 $3.61M $1.916M $-1.694M

Five-Year Company Overview

Income Statement

Income Statement Adial is still a pure development-stage biotech: it has essentially no product revenue and has reported recurring losses every year. Spending is mainly tied to research, clinical work, and overhead, so the income statement reflects a company investing in future potential rather than generating current profits. Losses per share have been volatile, partly affected by share count changes and the reverse split, but the underlying picture is consistent: the business is not yet self-sustaining and depends on outside capital while it pursues trials and approvals.

Balance Sheet

Balance Sheet The balance sheet looks very lean, with a small asset base and limited cash historically, but also no meaningful financial debt. Equity levels appear thin, suggesting that the cushion to absorb setbacks is modest. This combination points to a company with a light structure and no leverage burden, but also one that is financially fragile and highly sensitive to funding access, trial outcomes, and partner support.

Cash Flow

Cash Flow Cash flows from operations have been consistently negative, reflecting ongoing research and corporate costs without offsetting revenue. Investment spending has been modest, but free cash flow has still been negative, meaning cash has to be replenished periodically through equity raises or other financing. Overall, the cash profile fits a typical early‑stage biotech: cash is being consumed steadily, and the key question is how reliably the company can fund itself through the next major clinical milestones.

Competitive Edge

Competitive Edge Adial is positioned in a focused niche within addiction medicine, aiming to differentiate itself through a genetically targeted approach to Alcohol Use Disorder. Its main edge comes from its companion diagnostic, intellectual property around genetic markers, and data suggesting better responses in specific patient subgroups. However, it is a small company operating in a field where larger pharmaceutical firms and generic treatments dominate, and its lead program previously missed the main goal in an earlier large trial, which tempers its competitive standing until new, more targeted trials can validate the approach.

Innovation and R&D

Innovation and R&D Innovation is the core of Adial’s story. The company is pursuing personalized medicine for addiction, using genetic testing to identify patients more likely to respond to its lead drug candidate, AD04. The strategy builds on a known active ingredient but applies it in a new, low‑dose, genetically guided way, supported by a growing patent portfolio around biomarkers and treatment methods. The R&D roadmap includes a redesigned Phase 3 trial for Alcohol Use Disorder and exploratory opportunities in other addictions, which, if successful, could broaden the platform—but outcomes remain uncertain until further clinical data are available.

Summary

Adial is an early‑stage biotech with no commercial revenue yet and a history of operating losses, supported by a very light but fragile balance sheet and consistent cash burn. Its value proposition centers on a personalized, genetics‑based treatment for Alcohol Use Disorder, paired with a proprietary diagnostic and protected by patents. The company operates in a large, under‑served market but is small relative to potential competitors and heavily dependent on the success of a single lead program moving through later‑stage trials. Overall, the story is one of high scientific ambition and clear medical need, balanced by meaningful clinical, regulatory, and financing risks common to clinical‑stage biotech firms.

NEWS

October 17, 2025 · 9:00 AM UTC

Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show

Read more

October 9, 2025 · 8:30 AM UTC

Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution

Read more

September 16, 2025 · 8:00 AM UTC

Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04

Read more

September 3, 2025 · 8:30 AM UTC

Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule

Read more